Compare TRTX & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRTX | PSNL |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 647.8M | 729.1M |
| IPO Year | N/A | 2019 |
| Metric | TRTX | PSNL |
|---|---|---|
| Price | $8.50 | $9.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $9.83 | ★ $12.20 |
| AVG Volume (30 Days) | 461.7K | ★ 2.9M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 11.55% | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | $8.78 | $15.34 |
| Revenue Next Year | $4.14 | $41.46 |
| P/E Ratio | $14.82 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.57 | $3.84 |
| 52 Week High | $9.85 | $12.53 |
| Indicator | TRTX | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 55.75 | 55.00 |
| Support Level | $8.26 | $7.26 |
| Resistance Level | $8.72 | $11.28 |
| Average True Range (ATR) | 0.15 | 1.01 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 82.76 | 44.84 |
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.